Determination of non-motor symptoms in Parkinson’s disease in Kazakhstan (on the example of the city of Almaty)
Objective: To identify non-motor symptoms in patients with Parkinson's disease, depending on the severity of the disease. Background: Parkinson's disease is a chronic disease, as…CVT-301 treatment provides consistent and clinically significant improvements in Unified Parkinson’s Disease Rating Scale Part III (UPDRS-III) over 12 weeks
Objective: A post hoc analysis of UPDRS-III sequential changes over the 12-week treatment period of a phase 3 study. Background: CVT-301 is an inhaled levodopa…Phase I-II first-in-human clinical trial of intraputamenal CDNF in Parkinson’s disease: Exploratory fluid-based biomarker endpoints of the 12-month treatment period
Objective: To explore fluid-based biomarkers in subjects with advanced idiopathic Parkinson’s disease (PD) before and after intermittent intraputamenal monthly infusions of CDNF. Background: CDNF is…Parkinson Progression Marker Initiative 2.0 – New Science/New Cohorts
Objective: The Parkinson Progression Marker Initiative 2.0 (PPMI 2.0) is a longitudinal, observational, multi-center natural history study to assess progression of clinical features, digital outcomes,…The UP study – Ursodeoxycholic acid (UDCA) as neuroprotective treatment for Parkinson’s disease
Objective: To determine the safety and tolerability of ursodeoxycholic acid (UDCA) in Parkinson’s disease (PD) and explore its neuroprotective potential. Background: We previously undertook the…NILO-PD: A Phase 2A Study of Nilotinib in Patients with Moderately Advanced Parkinson’s Disease: Exploratory Efficacy Outcomes
Objective: To report secondary and exploratory analysis of efficacy of nilotinib in moderate/advanced Parkinson’s disease (PD) participants enrolled in NILO-PD study. Background: Previously completed studies…A pooled analysis of four pivotal, randomized controlled trials of istradefylline, an adenosine A2A receptor antagonist: Efficacy as adjunct to levodopa in Parkinson’s disease (PD)
Objective: To determine the efficacy of istradefylline combined with levodopa in PD patients experiencing motor fluctuations in a pooled analysis of 4 pivotal, randomized, placebo-controlled…Effects of a community-based adapted boxing program on physical capacity and quality of life in individuals with Parkinson disease over a 12 month period
Objective: The main objective was to assess long-term effects of a community-based adapted boxing program on physical capacity and QoL in individuals with mild, or…Motor subtype change between OFF and ON periods in patients with Parkinson’s disease
Objective: To identify if there is any difference in the motor subtype of PwPD between "off" stage and "on" stage. Background: Patients with Parkinson’s disease…Effect of the MAO-B inhibitor and glutamate modulator safinamide on depressive symptoms in three Parkinson’s disease patients
Objective: Patients suffering from Parkinson’s disease experience various motor and non-motor symptoms. Within the range of non-motor symptoms depression is reported as high as in…
- « Previous Page
- 1
- …
- 77
- 78
- 79
- 80
- 81
- …
- 149
- Next Page »